MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

RE-DESIGNATION OF DIRECTOR CHANGES IN SENIOR MANAGEMENT AND CHANGES IN COMPOSITION OF BOARD COMMITTEES

The board (the "**Board**") of directors (the "**Director(s)**") of MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that, with effect from August 26, 2026:

(i) Mr. Zhang Ruinian (張瑞年) ("**Mr. Zhang**") has resigned as the chief executive officer of the Company and has been appointed as the president of the Company;

(ii) Mr. Chen Guoming (陳國明) ("**Mr. Chen**") has resigned as the chairman of the Board, has been re-designated from a non-executive Director to an executive Director and has been appointed as the chief executive officer of the Company. He has also ceased to be a member of the audit committee of the Company (the "**Audit Committee**") and has been appointed as a member of the nomination committee of the Company (the "**Nomination Committee**"); and

(iii) Dr. Brian Chang ("**Dr. Chang**") has been appointed as the chairman of the Board and a member of the Audit Committee, and has ceased to be a member of the Nomination Committee.

Changes in the Role of Mr. Zhang

On August 26, 2026, the Board received the resignation letter of Mr. Zhang, in which he tendered his resignation as chief executive officer. On the same date, he has been appointed as the president of the Company. He will continue to serve as an executive Director and a member of each of the strategy committee and commercialization committee of the Company.

Changes in the Role of Mr. Chen

With the resignation of Mr. Zhang as chief executive officer of the Company, the Nomination Committee recommended Mr. Chen, the current chairman of the Board, as the chief executive officer of the Company. To satisfy the requirement of Code Provision C.2.1 of the Corporate Governance Code set forth in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), which provides that the roles of chairman and chief executive should be separate and should not be performed by the same individual, with effect from August 26, 2026, Mr. Chen has resigned as the chairman of the Board, has been appointed as the chief executive officer of the Company and has been re-designated from a non-executive Director to an executive Director. Mr. Chen has also ceased to be a member of the Audit Committee and has been appointed as a member of the Nomination Committee.

Mr. Chen has entered into a service agreement with the Company for a period of three years from the effective date of his re-designation, and shall be subject to re-election as and when required under the articles of association of the Company (the "**Articles of Association**") and the Listing Rules, until terminated in accordance with the terms and conditions of the service agreement or by either party giving to the other not less than 30 days' prior notice in writing. Pursuant to his service agreement, he is not entitled to receive director's fee from the Company. Mr. Chen's remuneration will be subject to annual review by the remuneration committee of the Company (the "**Remuneration Committee**") and the Board with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

Mr. Chen has confirmed that there is no other matter relating to his re-designation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and/or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Changes in the Role of Dr. Chang

The Nomination Committee recommended Dr. Chang as the chairman of the Board and with effect from August 26, 2026, Dr. Chang has been appointed as the chairman of the Board and will continue to serve as a non-executive Director.

Dr. Chang has confirmed that there is no other matter relating to his re-designation and new appointment that needs to be brought to the attention of the Shareholders of the Company (the "**Shareholders**") and/or the Stock Exchange.

Changes in Composition of Board Committees

Following the above changes with effect from August 26, 2026, (i) Dr. Chang has ceased to be a member of the Nomination Committee and been appointed as a member of the Audit Committee; and (ii) Mr. Chen has ceased to be a member of the Audit Committee and been appointed as a member of the Nomination Committee.

The Board would like to take this opportunity to welcome Dr. Chang, Mr. Chen and Mr. Zhang in their new roles.

Biographical details of Mr. Zhang, Mr. Chen and Dr. Chang

Mr. Zhang Ruinian (張瑞年), aged 62, has over 20 years of experience in the fields of cardiovascular, general surgery, orthopedics, neurosurgery and neurovascular, in vitro diagnosis, diabetes and medical analytical instruments. Mr. Zhang currently also holds directorships and management positions in several subsidiaries of our Group. From January 2023 to May 2024, Mr. Zhang served as the vice president of Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司), whose shares are listed on the Stock Exchange (stock code: 9877), where he also served as a consultant from July 2024 to March 2025. From April 2021 to December 2022, Mr. Zhang served as the general manager of the Greater China region at Corcym Medical Technology (Shanghai) Co., Ltd. (恪心醫療科技(上海)有限公司). From April 2018 to June 2020, he served as the chief executive director of Suzhou Jiecheng Medical Technology Co., Ltd. (蘇州傑成醫療科技有限公司). Prior to that, he also held senior management positions in various well known global and domestic companies, including Xi'an Janssen Pharmaceutical Co., Ltd. (西安楊森製藥公司), Rhone Poulenc Rorer S.A (China) Limited (羅納普朗克(中國)公司), Medtronic (China) Co., Ltd. (美敦力中國有限公司), Baxter Healthcare Co., Ltd., Edward Lifesciences Corporation (愛德華生命科學公司), Applied Biosystems Inc. (美國應用生物系統公司), Johnson & Johnson Medical (China) Ltd. (強生(中國)醫療器材有限公司), MicroPort®, Alcon Vision Products (China) Co., Ltd. (愛爾康(中國)眼科產品有限公司), among others.

Mr. Zhang obtained his bachelor's degree in clinical medicine from the Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院) (formerly known as the Shanghai Second Medical University) (前稱上海第二醫科大學) in July 1987, and his master's degree in business administration from the University of British Columbia in January 2004.

Mr. Chen Guoming (陳國明), aged 41, served as the chairman of the Board and a non-executive Director since August 29, 2023. He joined the Group as a vice president on September 1, 2016 and was mainly responsible for R&D since then. He served as an executive Director, president of the Company and general manager of Shanghai MicroPort CardioFlow Medtech Co., Ltd. (上海微創心通醫療科技有限公司) ("**MP CardioFlow**") from September 29, 2020 to August 29, 2023, and was redesignated as a non-executive Director. Mr. Chen currently also holds directorships in several subsidiaries of our Group including the chairman of the board of directors of MP CardioFlow since August 29, 2023. Mr. Chen has over 15 years' experience in R&D, clinical application and supply chain management of devices in the field of valves. Mr. Chen has served as first vice president of project & knowledge management and technology development of MicroPort®, since August 29, 2023. Before joining the Group in September 2016, he joined the MicroPort® Group in March 2010 and worked as senior R&D manager at Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司), from March 2010 to August 2016.

Mr. Chen obtained a bachelor's degree in engineering mechanics from Shanghai Jiao Tong University (上海交通大學) in China in June 2007 and a master's degree in mechatronics engineering from Shanghai Jiao Tong University in China in March 2010. He is also the inventor or a co-inventor of over 100 invention patents in China and overseas as of the date of this announcement.

As of the date of this announcement, Mr. Chen is interested in 1,781,178 ordinary shares of the Company held by him within the meaning of Part XV of Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

Save as disclosed below, as at the date of this announcement, Mr. Chen (i) has not held any other position in the Company or its subsidiaries; (ii) has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Dr. Brian Chang, aged 34, served as a non-executive Director of our Company since December 15, 2025. He has also served as the chief medical officer of MicroPort Scientific Corporation (微創醫療科學有限公司) ("**MicroPort®**, together with its subsidiaries, the "**MicroPort® Group**"), the controlling shareholder of the Company, whose shares are listed on the Stock Exchange (stock code: 0853) since June 2025. Dr. Chang, with a professional background as a physician-scientist and engineer, has over a decade of experience in the medical technology industry, having co-founded and led early-stage research, development, and business strategy at several medical technology ventures. Previously, Dr. Chang served as a postdoctoral and lecturer at Massachusetts Institute of Technology ("**MIT**"), where he oversaw interdisciplinary research teams and developed curriculum in cardiovascular physiology and medical technology. His academic research has focused on cardiac support devices and extracorporeal systems. He has authored 17 peer-reviewed publications and is a named inventor on multiple patents related to cardiovascular and extracorporeal technologies. Dr. Chang has been recognized through numerous honors, including the Paul & Daisy Soros Fellowship, the Seidman Prize for Outstanding Thesis, and teaching awards from both Harvard Medical School and MIT.

Dr. Chang obtained a bachelor's degree and a master's degree in mechanical engineering from Carnegie Mellon University in December 2013 and May 2014, respectively, graduating with University Honors and a minor in biomedical engineering. He obtained a Ph.D. in medical engineering and medical physics from the MIT in June 2018 and a M.D. from Harvard Medical School in May 2023, graduating magna cum laude. He completed his residency in Internal Medicine at Massachusetts General Hospital through the Stanbury physician-scientist program in June 2025.

Save as disclosed above, as at the date of this announcement, Dr. Chang (i) has not held any other position in the Company or its subsidiaries; (ii) has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

Save as disclosed above, the Board is not aware of any other information which is required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the re-designation of Mr. Chen and Dr. Chang that needs to be brought to the attention of the Shareholders and/or the Stock Exchange.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Brian Chang
Chairman

Shanghai, PRC, August 26, 2026

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Dr. Brian Chang and Mr. Deng Aoyi, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang, Dr. Hu Bingshan and Mr. Mao Junxiang.